Free Trial
NASDAQ:PGNY

Progyny (PGNY) Stock Price, News & Analysis

Progyny logo
$21.00 +0.38 (+1.84%)
As of 01/17/2025 04:00 PM Eastern

About Progyny Stock (NASDAQ:PGNY)

Key Stats

Today's Range
$20.37
$21.07
50-Day Range
$13.67
$21.00
52-Week Range
$13.39
$42.08
Volume
2.92 million shs
Average Volume
1.75 million shs
Market Capitalization
$1.79 billion
P/E Ratio
36.21
Dividend Yield
N/A
Price Target
$25.00
Consensus Rating
Hold

Company Overview

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Progyny Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
82nd Percentile Overall Score

PGNY MarketRank™: 

Progyny scored higher than 82% of companies evaluated by MarketBeat, and ranked 209th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Progyny has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 4 buy ratings, 9 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Progyny has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Progyny's stock forecast and price target.
  • Earnings Growth

    Earnings for Progyny are expected to grow by 8.47% in the coming year, from $0.59 to $0.64 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Progyny is 36.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.80.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Progyny is 36.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.34.

  • Price to Earnings Growth Ratio

    Progyny has a PEG Ratio of 1.95. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Progyny has a P/B Ratio of 3.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Progyny's valuation and earnings.
  • Percentage of Shares Shorted

    16.36% of the float of Progyny has been sold short.
  • Short Interest Ratio / Days to Cover

    Progyny has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Progyny has recently decreased by 4.59%, indicating that investor sentiment is improving.
  • Dividend Yield

    Progyny does not currently pay a dividend.

  • Dividend Growth

    Progyny does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.36% of the float of Progyny has been sold short.
  • Short Interest Ratio / Days to Cover

    Progyny has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Progyny has recently decreased by 4.59%, indicating that investor sentiment is improving.
  • News Sentiment

    Progyny has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 18 news articles for Progyny this week, compared to 7 articles on an average week.
  • Search Interest

    9 people have searched for PGNY on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Progyny to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Progyny insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,235,560.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    12.30% of the stock of Progyny is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Progyny's insider trading history.
Receive PGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter.

PGNY Stock News Headlines

Please take this warning seriously...
I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader in the country – in the next 30 days. In fact, I believe it could begin as soon as January 29th… Meaning you don’t have much time to prepare.
Progyny appoints Morris to board of directors
FY2024 EPS Estimates for Progyny Raised by Leerink Partnrs
See More Headlines

PGNY Stock Analysis - Frequently Asked Questions

Progyny's stock was trading at $17.25 at the beginning of 2025. Since then, PGNY shares have increased by 21.7% and is now trading at $21.00.
View the best growth stocks for 2025 here
.

Progyny, Inc. (NASDAQ:PGNY) released its quarterly earnings results on Tuesday, November, 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.37 by $0.26. The company's quarterly revenue was up 2.0% compared to the same quarter last year.

Progyny (PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Progyny's top institutional shareholders include Fort Washington Investment Advisors Inc. OH (1.72%), Nordea Investment Management AB (0.22%), International Assets Investment Management LLC (0.18%) and Janney Montgomery Scott LLC (0.08%). Insiders that own company stock include Tpg Gp A, Llc, Peter Anevski, Michael E Sturmer, Norman Payson, David J Schlanger, Mark S Livingston, Cheryl Scott and Kevin K Gordon.
View institutional ownership trends
.

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Progyny investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Rambus (RMBS), Voyager Therapeutics (VYGR), Saia (SAIA) and Waste Connections (WCN).

Company Calendar

Last Earnings
11/12/2024
Today
1/20/2025
Next Earnings (Estimated)
2/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
Healthcare
Current Symbol
NASDAQ:PGNY
Fax
N/A
Employees
310
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$43.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+19.0%
Consensus Rating
Hold
Rating Score (0-4)
2.31
Research Coverage
13 Analysts

Profitability

Net Income
$62.04 million
Pretax Margin
7.18%

Debt

Sales & Book Value

Annual Sales
$1.09 billion
Cash Flow
$0.75 per share
Book Value
$5.77 per share

Miscellaneous

Free Float
74,679,000
Market Cap
$1.79 billion
Optionable
Optionable
Beta
1.31

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:PGNY) was last updated on 1/20/2025 by MarketBeat.com Staff
From Our Partners